Top-News

Anixa Biosciences Aktie News

Aktie
WKN:  A2N6ZF ISIN:  US03528H1095 US-Symbol:  ANIX Branche:  Biotechnologie Land:  USA
4,74 $
+0,00 $
0,00%
4,0692 € 04.12.25
Depot/Watchlist
Marktkapitalisierung *
113,88 Mio. €
Streubesitz
78,02%
KGV
-11,80
Index-Zuordnung
-

Anixa Biosciences News

04.12.25 - Hotstock Investor
Revolutionäre Technologie: Einmalige Investmentchancen in den potenziellen Gamechanger der Krebsbehandlung
An der Börse eröffnen sich selten Gelegenheiten, die das Potenzial haben, einen ganzen globalen Markt grundlegend neu zu definieren. Die nächste Generation der ...
03.12.25 - Hotstock Investor
Impfstoff gegen Krebs: Brustkrebsmittel: Anixa präsentiert bahnbrechende Daten nächste Woche!
Jetzt können Sie hier noch einsteigen, bevor die Börse begreift, was hier eigentlich passiert: eine mögliche Entwicklung eines revolutionären Impfstoffs gegen Krebs.
17.11.25 - IRW-Press
Anixa Biosciences gibt bekannt, dass die Weltgesundheitsorganisation (WHO) den internationalen Freinamen für seine CAR-T-Therapie genehmigt hat
Anixa Biosciences gibt bekannt, dass die Weltgesundheitsorganisation (WHO) den internationalen Freinamen für seine CAR-​T-Therapie genehmigt hat - dies ist ein wichtiger ...
17.11.25 - PR Newswire
Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization
Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-​Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global ...
12.11.25 - PR Newswire
Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s
Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s PR Newswire
10.11.25 - PR Newswire
Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025
Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025 PR Newswire
05.11.25 - PR Newswire
Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic
Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic PR Newswire
23.10.25 - PR Newswire
Anixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference
Anixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference PR Newswire
20.10.25 - PR Newswire
Anixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology
Anixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology PR Newswire
08.10.25 - PR Newswire
Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034
Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034 PR Newswire
08.10.25 - PR Newswire
Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034
Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034 PR Newswire
07.10.25 - PR Newswire
Anixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial
Anixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial PR Newswire
22.09.25 - PR Newswire
Cleveland Clinic to Present Final Results of Phase 1 Clinical Trial for Anixa Biosciences' Breast Cancer Vaccine at 2025 San Antonio Breast Cancer Symposium
Cleveland Clinic to Present Final Results of Phase 1 Clinical Trial for Anixa Biosciences' Breast Cancer Vaccine at 2025 San Antonio Breast Cancer Symposium PR Newswire
16.09.25 - PR Newswire
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals PR Newswire
16.09.25 - PR Newswire
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals PR Newswire
08.09.25 - PR Newswire
Anixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival
Anixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival PR ...
02.09.25 - PR Newswire
Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference PR Newswire
25.08.25 - PR Newswire
Anixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Anixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference PR Newswire
20.08.25 - IRW-Press
Anixa Biosciences erhält von der Chinese National Intellectual Property Administration eine Patentbewilligung für seine Brustkrebsimpfstoff-Technologie
Mit dem Zulassungsbescheid erhält Anixa das erste chinesische Patent für seinen Brustkrebsimpfstoff Der globale Schutz des geistigen Eigentums wird auf Märkte mit hoher ...
20.08.25 - PR Newswire
Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology
Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology PR Newswire

Newssuche

Videos

newspaper
02.12.25 +8,18%
Technical Trading: DAX Long dienstags
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »